Nichole Moore1, Michael Kohut2, Henry Stoddard2, Debra Burris2, Frank Chessa1, Monica K Sikka3, Daniel Solomon4, Colleen M Kershaw5,6, Ellen Eaton7, Rebecca Hutchinson1,2,8, Kathleen M Fairfield1,2,8, Thomas J Stopka9, Peter Friedmann10,11, Kinna Thakarar1,2,8. 1. Tufts University School of Medicine, Boston, MA, USA. 2. Center for Interdisciplinary Population and Health Research, MaineHealth Institute for Research, Portland, ME, USA. 3. Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, OR, USA. 4. Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA. 5. Section of Infectious Disease and International Health, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. 6. Geisel School of Medicine at Dartmouth, Hanover, NH, USA. 7. Division of Infectious Disease, The University of Alabama at Birmingham, Birmingham, AL, USA. 8. Maine Medical Center, Portland, ME, USA. 9. Department of Public Health & Community Medicine, Tufts University School of Medicine, Boston, MA, USA. 10. Office of Research, UMass Chan Medical School-Baystate, Springfield, MA, USA. 11. Frank Chessa is also affiliated to MaineHealth Institute for Research, Portland, ME, USA; Maine Medical Center, Portland, ME, USA.
Abstract
Background: Patients with injection drug use (IDU)-associated infections traditionally experience prolonged hospitalizations, which often result in negative experiences and bad outcomes. Harm reduction approaches that value patient autonomy and shared decision-making regarding outpatient treatment options may improve outcomes. We sought to identify health care professionals (HCPs) perspectives on the barriers to offering four different options to hospitalized people who use drugs (PWUD): long-term hospitalization, oral antibiotics, long-acting antibiotics at an infusion center, and outpatient parenteral antibiotics. Methods: We recruited HCPs (n = 19) from a single tertiary care center in Portland, Maine. We interviewed HCPs involved with discharge decision-making and other HCPs involved in the specialized care of PWUD. Semi-structured interviews elicited lead HCP values, preferences, and concerns about presenting outpatient antimicrobial treatment options to PWUD, while support HCPs provided contextual information. We used the iterative categorization approach to code and thematically analyze transcripts. Results: HCPs were willing to present outpatient treatment options for patients with IDU-associated infections, yet several factors contributed to reluctance. First, insufficient resources, such as transportation, may make these options impractical. However, HCPs may be unaware of existing community resources or viable treatment options. They also may believe the hospital protects patients, and that discharging patients into the community exposes them to structural harms. Some HCPs are concerned that patients with substance use disorder will not make 'good' decisions regarding outpatient antimicrobial options. Finally, there is uncertainty about how responsibility for offering outpatient treatment is shared across changing care teams. Conclusion: HCPs perceive many barriers to offering outpatient care for people with IDU-associated infections, but with appropriate interventions to address their concerns, may be open to considering more options. This study provides important insights and contextual information that can help inform specific harm reduction interventions aimed at improving care of people with IDU-associated infections.
Background: Patients with injection drug use (IDU)-associated infections traditionally experience prolonged hospitalizations, which often result in negative experiences and bad outcomes. Harm reduction approaches that value patient autonomy and shared decision-making regarding outpatient treatment options may improve outcomes. We sought to identify health care professionals (HCPs) perspectives on the barriers to offering four different options to hospitalized people who use drugs (PWUD): long-term hospitalization, oral antibiotics, long-acting antibiotics at an infusion center, and outpatient parenteral antibiotics. Methods: We recruited HCPs (n = 19) from a single tertiary care center in Portland, Maine. We interviewed HCPs involved with discharge decision-making and other HCPs involved in the specialized care of PWUD. Semi-structured interviews elicited lead HCP values, preferences, and concerns about presenting outpatient antimicrobial treatment options to PWUD, while support HCPs provided contextual information. We used the iterative categorization approach to code and thematically analyze transcripts. Results: HCPs were willing to present outpatient treatment options for patients with IDU-associated infections, yet several factors contributed to reluctance. First, insufficient resources, such as transportation, may make these options impractical. However, HCPs may be unaware of existing community resources or viable treatment options. They also may believe the hospital protects patients, and that discharging patients into the community exposes them to structural harms. Some HCPs are concerned that patients with substance use disorder will not make 'good' decisions regarding outpatient antimicrobial options. Finally, there is uncertainty about how responsibility for offering outpatient treatment is shared across changing care teams. Conclusion: HCPs perceive many barriers to offering outpatient care for people with IDU-associated infections, but with appropriate interventions to address their concerns, may be open to considering more options. This study provides important insights and contextual information that can help inform specific harm reduction interventions aimed at improving care of people with IDU-associated infections.
Substance use and infectious complications from injection drug use (IDU) have reached
epidemic proportions in the United States.[1,2] Patients with serious
infections usually have limited outpatient treatment options and long, costly
hospitalizations.[3] While remaining hospitalized for the entire course of
treatment might be perceived as the safest treatment option, prolonged
hospitalization is not benign.[4] However, there are no clear
guidelines or protocols for hospital discharge decision-making for people who use
drugs (PWUD). Growing evidence suggests that outpatient parental antimicrobial
therapy (OPAT) among PWUD, step-down approaches from intravenous (IV) to oral
antibiotics, and long-acting IV antibiotic infusions are effective for certain
patients and shorten hospital stays.[5-9] Despite the evidence, patients
are often not given a chance to explore these outpatient treatment
options.[10]Prior research suggests that a harm reduction approach to caring for people with
substance use disorders (SUDs) reduces stigma and improves engagement in health
care.[11-16] It promotes low barrier
access to services, respects patient autonomy, and, while recognizing abstinence as
ideal, accepts alternatives that reduce harms.[17] A harm reduction approach to
caring for patients with infectious complications related to IDU would (a) be
sensitive to how stigmatizing medical encounters exacerbate harms, (b) prioritize
the concerns of patients and ensure their involvement in making shared decisions
about their care, and (c) consider a full range of options even in cases where a
patient is not abstaining from drug use.[18,19]Despite a common ethos of beneficence toward patients, scholarship suggests that the
harm reduction model sometimes clashes with paternalistic medical models. In a
paternalistic medical model, physicians are experts who know the best treatment
option and encourage treatment ‘compliance’ from patients whose autonomy is impaired
by addiction. Harm reduction, by contrast, sees a person who uses drugs as having
agency and expertise based on their lived experience.[20] Discordance between the
models may present barriers to implementation of harm reduction approaches in health
care settings.We performed a qualitative study to identify the barriers and facilitators to
implementing harm reduction principles in the care of hospitalized patients with
infectious complications of IDU. We conducted interviews with health care
professionals (HCPs) who elicited the factors they consider relevant to four
infection treatment options: long-term hospitalization, oral antibiotics,
long-acting antibiotics at an infusion center, and outpatient parenteral
antibiotics. These findings will enable us to design collaborative interventions and
harm reduction-based treatment decisions.
Methods
Study design
This analysis was part of a larger study which used in-depth qualitative
interviews with HCPs, community partners, and patients to better facilitate
shared decision-making between hospital staff and patients hospitalized with
IDU-associated infections. Given the breadth of participant perspectives, this
study focuses only on HCP perspectives to better understand barriers HCPs
experience to offering outpatient treatment options to hospitalized PWUD. To
ensure inclusion of relevant information and to understand the hospital
environment in which PWUD are receiving care, we included both HCPs who are
directly involved with discharge decision-making (lead HCPs) and other HCPs
experienced with and involved in the treatment of PWUD in the hospital, such as
palliative care physicians, pharmacists, and addiction counselors (support HCPs)
(Table 1).
Table 1.
Description of study population, stratified by lead and support HCPs.
Service
Lead HCPs[a]
N = 8
Support HCPs[b]
N = 11
Subspecialists
Addiction
–
4
Infectious diseases
3
2
Palliative care
–
1
Hospitalist
5
–
Care management/Nursing administration
–
4
HCP, health care professionals.
Lead HCPs defined as those involved with decision-making.
Support HCP defined as those providing supporting information about
the contexts of the decisions.
Description of study population, stratified by lead and support HCPs.HCP, health care professionals.Lead HCPs defined as those involved with decision-making.Support HCP defined as those providing supporting information about
the contexts of the decisions.
Study population and recruitment
We recruited HCPs (n = 19) from a 637-bed, academic, tertiary
care medical center located in Portland, Maine using theoretical sampling to
include a diversity of perspectives relevant to discharge decision-making and
the harm reduction approach. Participants were colleagues of K.T. who recruited
them by email. We sampled lead HCPs until we achieved thematic saturation, where
additional interviews were not producing new information. We sampled support
HCPs to provide a breadth of theoretically relevant knowledge rather than
thematic saturation. Consistent with our theoretical sampling approach, we
continued to recruit participants as long as our data suggested their input was
theoretically relevant.[21]
Methods
A trained and experienced interviewer (M.K.) conducted all interviews using a
piloted semi-structured interview guide that encouraged participants to reflect
on specific experiences with patients with a history of IDU. The interview
probed factors relevant to treatment decisions, instances in which specific
treatment options were considered, and experiences with patients who underwent
self-directed discharge. The final portion of the interview elicited beliefs and
attitudes toward shared decision-making with PWUD. HCPs participated in
interviews by phone or videoconference call due to COVID-19 restrictions and
lasted between 30 and 60 min. Interviews were digitally recorded and transcribed
verbatim by a professional medical transcription service.Analysts redacted any information that could be used to identify participants.
Two authors indexed and thematically analyzed the transcripts using MAXQDA
software and iterative categorization, a systematic approach that uses both
deductive and inductive codes to first describe and then interpret qualitative
data.[22] Following indexing, analysts generated themes, which are
patterns that appeared across topics and which related to the research
aim.[23] The analytical team evaluated the robustness of themes
through review of supporting excerpts and consideration of alternative
interpretations.
Results
The 19 participants in the sample included 8 lead HCPs and 11 support HCPs with a
breadth of expertise (Table
1).We present five themes relevant to our aim: (1) availability of resources; (2) the
uneven distribution of knowledge about treatment options and community resources;
(3) the notion that hospitals protect against structural harms; (4) degree of HCPs’
trust in PWUD to make treatment decisions; and (5) how hospital discharge
responsibility is shared.
Resources supporting feasibility of outpatient options
HCPs recognized a variety of resources as necessary for patients to be successful
with outpatient options, and lack of such resources can be a barrier. Lead HCPs
said structural determinants, such as housing instability and lack of social
support, impact the viability of outpatient options. Lead HCPs generally agreed
that patients experiencing such issues were not good candidates for outpatient options:. . .even if it was a possibility to [. . .] have them discharged [. . .]
with the PICC line, if they don’t have housing, where is all the
antibiotic going to be stored? There’s no refrigerator. Where’s home
health going to meet them? How is the PICC line going to stay clean?
Same thing with the oral antibiotics. So, how is the patient going to
make sure that they don’t lose the antibiotic if they don’t have a house
to keep it in?. (Infectious Disease Physician – Lead HCP 16)HCPs reported that patients living in rural areas or those with ‘inconvenient and
unreliable transportation’ would struggle filling prescriptions for oral
antibiotics or traveling to infusion centers. Lead HCPs also recognized that, in
light of these structural issues, following-up with medical care is challenging
for patients.While resources exist to address these barriers, they are limited. Staff
shortages and stringent home health criteria (i.e. needing to be ‘homebound’)
were barriers, and many HCPs reported challenges finding home health agencies
willing to work with PWUD:. . .that’s what we were told [even] for people who were housed [. . .]
the added complication of home health places refusing to go into any
home that has injection drug use. Even a history of injection drug use.
[. . .] I wonder if, is it really a policy or is it a decision that they
make that isn’t a policy, but just an unwritten opinion. (Addiction
Professional – Support HCP 8)Furthermore, insurance gaps limit treatment options. Cost was often cited as a
‘number one challenge’ for outpatient treatment options. Home health aides
necessary for OPAT, access to infusion centers, and oral antibiotics all
typically require insurance coverage and approval:They do need to have insurance to pay for [home health] services. We’ve
run into times where we have had people privately pay, but I found out
that for visiting nurses and visiting physical therapy, it was $200 per
session, per service. And that was one visit. And these patients require
multiples. So sometimes it’s not feasible for many people. (Nurse
Manager – Support HCP 18)Even for insured patients, prior authorization poses an additional barrier to
receiving services in a timely manner, particularly if an antimicrobial is not
standard of care.In summary, resources related to structural determinants of drug use and related
harms are insufficient and objectively limit outpatient treatment options for
patients experiencing these structural harms, such as homelessness and lack of
insurance. HCPs recognize these limitations as unchangeable and therefore do not
offer all outpatient treatment options.
Knowledge among health care providers
Gaps in knowledge among HCPs could also shape which treatment options are
offered. Many lead HCPs were not aware of community resources available to
support patients:. . .a lot of providers don’t even know these resources. I just happen to
have fallen into this little niche where I know people. [. . .] If this
isn’t your area of care, then you’re just like, ‘Well, I don’t know,
they just discharge like everybody else’. (Hospitalist – Lead HCP 9)There was uncertainty about whether specific resources, such as home health aides
and space at infusion centers, would be available for PWUD. Several HCPs
believed that a home health agency would not consider a patient for services who
had a history of SUD or unstable housing:The home health companies, for a long time, which I can’t speak to them
very recently, a lot of them were just a flat out no if they had a
history of IV drug use. So absolutely, 100%, some of the barrier was
just no company to do it. (Hospitalist – Lead HCP 11)However, a nurse manager (HCP 18) and a manager of a home health organization
(HCP 19) confirmed that most agencies are willing to visit patients, including
those with a history of drug use, in a shelter or halfway house under certain
circumstances in which the location was safe (e.g. free of violence) for both
parties, and there was a private, clean area for antibiotic administration.Knowledge of antimicrobial options was a second area of concern. Lead HCPs
without infectious disease specialization expressed reluctance about prescribing
any antibiotic that was not standard of care. Many lead HCPs believed that oral
antibiotics were less effective than daily IV antibiotics. Because of this
perceived lower efficacy, they tended to offer oral antibiotics only as a
contingency plan when patients choose self-directed discharge. However, an
infectious disease pharmacist noted that if the organism and severity of the
infection allow, there are evidence-based oral antibiotics that are effective
against IDU-associated infections, especially if the patient has already
received an initial course of IV antibiotics. This approach did not seem to be
common knowledge among HCPs without infectious disease specialization.These various gaps in knowledge contributed to lead HCPs not offering the full
spectrum of discharge options for patients. Some participants suggested that
clear and up-to-date guidelines would help when expert consultation is not
feasible.
Hospitals perceived as protective
Lead HCPs were reluctant to offer outpatient options in place of prolonged
hospitalization because they believed that they were promoting patient
well-being and preventing undue harm from forces extrinsic to the hospital.
Implicit in these views is that the hospital is a refuge that protects patients
from poor health outcomes and return to substance use:. . .We always worry about relapse into substance use when someone leaves
the hospital. And if someone’s supposed to be taking daily antibiotics
or going to an infusion center, but they get back into using heroin or
stimulants, that’s much less likely to happen. So, I think we worry
about that follow up and consistency. . .and, maintaining the
cleanliness of that line and safety of that line while they’re out in
the community. (Hospitalist – Lead HCP 5)At least if they’re in the hospital, they’re as protected as we can make
them, but out in the community, there’s just no protection. (Addiction
Professional – Support HCP 8)However, lead HCPs also recognized that hospitalization can be harmful due to
stigmatizing encounters, reliving traumatic experiences, or nosocomial
infections. Some HCPs recognized that patients may delay seeking medical care
due to fears of mistreatment based on previous experiences of feeling
disrespected, stigmatized, or judged in hospitals:[For a lot of patients] just the idea of setting foot inside [the
hospital] is they can’t handle it. And a lot of times, that’s because of
treatment that they’ve had in the emergency department. Like I said, it
just takes one or two bad encounters to develop a lot of medical related
trauma. And then they come in [to clinic] with fevers and sweats and
huge abscesses and I’m like, ‘You got to go. You got to go for this
one’. And they don’t go. . . (Infectious Disease Physician – Lead HCP
6)Many lead HCPs acknowledged that stigmatization may motivate patients to
discharge themselves before treatment is complete. They pointed out that
practices such as room searches, indoor confinement, and lack of freedom
resemble a jail-like environment, which is triggering for some patients:. . . It’s like a jail to them, they can’t have their friends, everything
searched, everybody is very distrusting of them, which is always not a
good way to start the relationship. . . (Infectious Disease Physician –
Lead HCP 11)Although the hospital could help patients by connecting them to resources, this
is not always the reality:Part of me likes having patients stay in the hospital. Not in the current
model that we use, but I like the idea of having them be a captive
audience. If we could really bridge the gap with outpatient services and
utilize the time to have vocational services and have other really
in-depth root cause, changing their social determinants of health, if we
could help them get housing. If we could change those things that may
actually change their disease process, well then maybe that time is
beneficial. Right now that time is not beneficial. (Hospitalist – Lead
HCP 9)Many lead HCPs were resistant to discharging people with history of IDU with a
peripherally inserted central catheter (PICC), citing concerns about misuse, but
others observed that patients can and do inject substances through their PICC
while in the hospital:Everyone often talks about like, ‘Oh, what if they inject through the
PICC line?’ I’m not actually worried about them injecting through the
PICC line because you can talk to them about that and people who inject,
do it in the hospital as well as home. I mean we’re not protecting them
by keeping them in hospital. It’s not they’re not necessarily injecting.
People do it all the time . . . (Infectious Diseases Physician – Lead
HCP 6)In summary, most HCPs believed that long-term hospitalization is the safest
option for PWUD because hospitals can be protective against structural
determinants of substance use and related harms. HCPs aware of the limitations
and harms associated with hospitalization were more open to outpatient
alternatives.
Patient capability for decision-making
A harm reduction approach centers patient autonomy in making informed discharge
decisions. Many HCPs described how including patients in decisions may encourage
more engagement and avoid the negative consequences of self-directed discharge:. . . I think it’s really important to involve the patient in the
conversation and you’re going to be a lot more successful in getting
people to stay if they buy in . . . (Hospitalist Lead – HCP 6)But I’d like for [an early discharge conversation] to be an option more
in the future because it allowed this patient to have some agency and to
make their needs known and to really be part of their care plan in a way
that seemed dignified. (Social Worker – Support HCP 12)However, interviews revealed fears that the patients would make the ‘wrong
choice’, potentially leading to worse outcomes. Some HCPs would not even tell
patients about outpatient options, citing concerns about patient judgment:I’m not a physician that writes in my note, ‘if patient decides to have a
self-directed discharge, give them doxycycline’. I think I worry that if
that’s relayed to the team, it might be relayed to the patient. [. . .]
And I think once a team or a patient hears that, they may think that the
therapy would be equivalent, and why would they stay? (Infectious
Diseases Physician – Lead HCP 16)HCPs were concerned that patients might not understand the relative efficacy of
the options or the severity of their infections. These fears are greatest
earlier in a patient’s hospitalization, when withdrawal, pain, and other
stressors can significantly affect decision-making:Obviously a lot of times patients come in and they’re withdrawing from
their substances. So, I think that’s not a good time. [. . .] once their
pain and withdrawals are under control, that would be a good time to
talk about it as soon as possible. (Hospitalist – Lead HCP 5)Past experiences also shaped how lead HCPs thought about offering these
antimicrobial treatments, and several reported greater reluctance after being
‘burned’ by patients who did not complete outpatient treatment. The greatest
doubts were expressed for OPAT:My main concern would be the misuse of line. That would be my first
concern, to use the line to inject drugs and certainly lead to the
complications, including much worse infections they’ve been treated
initially for. (Infectious Diseases Physician– Lead HCP 15)It’s almost like you’re just giving them easy access to inject . . . And
if they got the urge, what is there to stop them from just injecting
right into the PICC because our patients sometimes are very impulsive.
(Addiction Professional – Support HCP 4)Concerns about PWUD making poor decisions about their care were closely tied with
whether an HCP believed the patient would continue to use substances:So I think sort of safety and community support, how engaged are they in
recovery, if their attitude is that they’re going to just go right back
out and continue to use then sending them out say with a PICC line,
maybe a less desirable option. (Hospitalist – Lead HCP 14)Are they going to be able to take oral antibiotics with reasonable
adherence for somebody who has very high methamphetamine use? Sometimes
I really worry about their ability to be organized enough to take the
medications. (Hospitalist – Lead HCP 6)There were various opinions on whether, and for how long, a patient should
abstain from drug use before being offered OPAT. Only one lead HCP (Hospitalist)
indicated openness to considering the option for a patient with ‘functional and
controlled’ substance use. Most lead HCPs required some degree of SUD treatment,
and one suggested that patients need at least 1 year of sobriety.However, some HCPs emphasized that patient preferences should be discussed, even
when those preferences are against what HCPs believe to be the best treatment
course for the patient. One support HCP noted that withholding options such as
oral antibiotics may backfire:It may help to present [oral options] to patients. Now, I understand the
pros and cons of that: the moment you plant the seed in the patient,
then that’s the expectation [. . .] that’s all the patient might be
fixated on. But I think [. . .] the moment you say, ‘We’re going to see
you for the next six weeks here’, they’re already thinking about, ‘When
am I going to leave AMA?’ (Pharmacist – Support HCP 3)The potential for patients to self-discharge means that they are ultimately
involved in decisions about hospitalizations regardless of provider preference:[Patients] make the decision to leave against medical advice all the
time. Right? And we have to accept it. We can’t force them to do things
we want [. . .] if they have capacity. [. . .] Some people might view
taking oral antibiotics and leaving as a bad decision, but you know, it
might be the best decision for that person. (Palliative Care Physician –
Support HCP 13)It’s totally appropriate to offer second line treatment when the patient
has declined the safer alternative and understands that it might not
work. But you also have to give them the knowledge of what that looks
like and at least try to set them up for success. (Hospitalist – Lead
HCP 6)Responding to concerns among their colleagues about PICC misuse, HCPs with
extensive experience with PWUD advised against focusing on such concerns,
recognizing that if a patient is going to inject substances, they can do so
without a PICC:It doesn’t seem to me that having a PICC line available is going to
change anybody’s mind about injecting drugs versus not. (Hospitalist –
Lead HCP 5)One nurse participant (support HCP) reported how a patient had explained, ‘that’s
really offensive to me because I don’t need a PICC line to use drugs. I have
other ways to use drugs’. Some HCPs suggested misuse was unlikely. A nurse with
a long history of working with PWUD in an outpatient setting claimed that most
patients were actually fearful of injecting into the PICC due to likely
overdose, are more likely to inject where they are accustomed to injecting (e.g.
between the toes), and had never heard of anyone injecting directly into a PICC.
Reflecting on these concerns, another lead HCP suggested that efforts to predict
misuse may be inappropriate:Well, I mean of course having a PICC line available for drug use seems
like a scary idea, you’re just allowing people to use. But the flip side
of that I think and what I’ve learned from harm reduction is that [. .
.] maybe that’s not for us to make prejudgments about. (Hospitalist–
Lead HCP 9)In summary, while HCPs see value in involving patients in decisions about their
treatment course, many were hesitant to trust that patients with SUD are capable
of choosing wisely among discharge options. HCPs who were more likely to offer
all outpatient options insisted on the importance of patient autonomy,
regardless of substance use history.
Responsibility for patient outcomes
A central question HCPs raised is over who bears responsibility if they offer
outpatient antimicrobial options to PWUD and the patient has a bad outcome:. . .I could see that patients should be at least in part responsible for
these outcomes, but we as physicians, this is what we do. We take
responsibility, we take charge. Patients are under our care. So, it is
something that we assume responsibility for, for these situations, for
their care during this treatment and potential complications. (ID
Physician – Lead HCP 15)This question is complicated by frequent changes in the care team over the course
of a patient’s hospital stay. Some hospitalists preferred to avoid the issue by
deferring to infectious disease specialists regarding all decisions about treatment:. . .because I’m not an expert, I don’t feel comfortable with being
responsible for somebody leaving with a line. So I would defer to the
infectious disease specialists, and I would also in my deferral to them,
allow them to accept the responsibility for that. (Hospitalist – Lead
HCP 10)The following excerpt furthermore speaks to a sense among other HCPs that
providing a PICC would make them partially responsible for adverse outcomes or a
patient’s drug use:I think that’s another concern, is if patients go out and that line
itself gets infected. It goes back to who inserted it. It would look
potentially bad on the institution, then, if the patient ends up getting
a line related infection. (Pharmacist – Support HCP 3)However, some HCPs countered that liability should only be a concern when HCPs
provide ‘substandard care’ that lacks a safe transition to outpatient care or
does not provide adequate education regarding the safe use of the PICC:The liability I think comes when you give them substandard care when you
could have given better care or when you don’t attempt to provide any
care or support or treatment that allows them a reasonable chance at a
safe transition to the outpatient world. (Hospitalist – Lead HCP 6)Some HCPs asserted that the risk of PICC misuse also needs to be weighed against
the risk that a patient will undergo in self-directed discharge without
completing treatment, reflecting on liability and respect for patients:It seems like providers are really concerned about the liability of
somebody leaving with PICC line and using, but they’re not necessarily
concerned about the liability of not treating patients with respect,
having them leave the hospital early and then returning to active use in
the absence of treatment. (Addiction Professional – Support HCP 1)As with gaps in knowledge, some HCPs suggested that such concerns could be
addressed by implementing clear guidelines and harm reduction-based policies,
which could offload responsibility from individual HCPs.
Discussion
Through qualitative interviews with HCPs, we collected contextual information for
hospital discharge decision-making in people with IDU-associated infections and
identified barriers to outpatient treatment options. While most HCPs seemed open to
discussing outpatient options in some contexts, several barriers were apparent. HCPs
may default to inpatient IV antimicrobials based on misconceptions about existing
resources and treatment efficacy of non-standard options, such as oral or
long-acting antimicrobials. Several HCPs felt that the hospital could help alleviate
some structural problems associated with substance use (for example, housing
insecurity and access to SUD treatment), while many also recognized that some
patients have negative experiences in the hospital that alienate PWUD from medical
systems. Some HCPs were further concerned that if they presented all possible
treatment options, patients may choose an inappropriate or ineffective option in
favor of leaving the hospital prematurely. This concern may reflect HCPs’ lack of
trust in the ability of PWUD to make good decisions about their care. Finally,
uncertainty about who might be held responsible for any poor outcomes with
outpatient treatment led some HCPs to only consider inpatient treatment options for
patients who have a history of SUD.Although some of the barriers to outpatient care were unmodifiable, several barriers
could be alleviated by creating a shared understanding of the structural
determinants of substance use and related harms, as outlined in the Harm Reduction
Implementation Framework (HRIF) (Table 2). The HRIF is a seven-step
framework to help organizations fully and effectively implement a harm reduction
approach that is contingent on a commitment to social justice and reducing stigma
through incorporating experiential voices and evidence-based practices.[17] For example,
rather than basing decisions solely around assessments of whether a patient will use
the PICC for injecting drugs, HCPs should be fully aware of the actual structural
barriers to OPAT, such as unstable housing and insurance status. Addressing these
structural determinants of substance use, (e.g. housing for patients experiencing
homelessness), may reduce the barriers to offering outpatient treatment options to
patients. Implementation of programs and team-based approaches such as integrated
treatment for SUD can also address some of these structural barriers.[5] Key components
of this approach include an interdisciplinary team of infectious disease and
addiction medicine clinicians, infusion nurses, pharmacists, case managers, social
workers, and caregivers.[24] This integrated, multidisciplinary team approach, where
patients receive both antimicrobial and SUD treatment, has been shown to improve
patient outcomes, such as reduced length of stays.[25]
Table 2.
Summary of study themes, potential interventions, and HRIF tenets.[a]
Theme
Intervention
HRIF tenet
Inadequate resources
- Address and change structural barriers, such as housing
insecurity.- Utilize team-based approaches to care.
#1
Knowledge gaps
- Address knowledge gaps in PICC misuse, antimicrobial efficacy,
and existing community resources.- Harm reduction
education.- Team-based approaches to care.
#1#3
Hospital as protective
- Address stigmatization and mistreatment in hospital through
effective leadership and organizational
culture.- Address restrictive hospital policies.
#3
Trust in patients
- Include patient voices in decision-making.- Assess for
capability to make decisions.
#2
Responsibility
- Implement harm reduction-based guidelines on
discharge.- Utilize interdisciplinary teams.
HRIF, Harm Reduction Implementation Framework; PICC, peripherally
inserted central catheter.
HRIF tenets (1) create a shared understanding of the structural
determinants of substance use and related harms, (2) ensure meaningful
inclusion of experiential voices in policies, programs, and services,
and (3) promote an organizational culture of harm reduction.
Summary of study themes, potential interventions, and HRIF tenets.[a]HRIF, Harm Reduction Implementation Framework; PICC, peripherally
inserted central catheter.HRIF tenets (1) create a shared understanding of the structural
determinants of substance use and related harms, (2) ensure meaningful
inclusion of experiential voices in policies, programs, and services,
and (3) promote an organizational culture of harm reduction.In this study, we found that misconceptions around PICC misuse and inferiority of
outpatient antimicrobial options were common. Prior studies have shown that PICC
misuse is relatively uncommon among PWUD.[9] Moreover, in select groups of
patients, growing evidence supports that oral antimicrobials can be as effective as
IV antimicrobial options.[26,27] Many clinicians may still consider IV antibiotics as first-line
therapy, but this approach may be based on personal experience, rather than
evidence-based practice.[28] Addressing knowledge gaps in PICC misuse and educating HCPs
on new and current antimicrobial research are important for facilitating a harm
reduction approach to discharge decision-making. Also, addressing knowledge gaps on
factors that facilitate outpatient treatment, such as home health policies and
community resources, would further allow HCPs to expand treatment options for
patients.Most HCPs in this study expressed concern that other care team members would not be
supportive of offering all discharge options. This view further highlights the
importance of education and other methods to address differences in care
philosophies. The HRIF points out that creating an organizational culture of harm
reduction and utilizing effective hospital leadership to ensure organizational
culture shifts can prevent widespread stigmatization and improve outcomes.[17] An
organization with a culture of harm reduction is one in which staff feel safe
discussing substance use and harm reduction, and they are provided with educational
opportunities that improve patient care.[17] This training would include
sharing evidence-based examples of successful harm reduction implementation and
firsthand stories from patients. OPTIONS-DC, a multidisciplinary and
interprofessional care conference developed at Oregon Health & Science
University, works under harm reduction and patient-centered models to identify
treatment options which are acceptable to both patients and HCPs, and investigators
demonstrated that it is entirely feasible to integrate practices of harm reduction
into treatment for patients who need long-term antibiotic treatment.[29] Other studies
have shown that hospital-based harm reduction promotes patient-centered
care.[30] In our study, many participants emphasized harm reduction
principles and the importance of prioritizing the needs and preferences of PWUD,
even when those preferences are against what HCPs believe to be the best treatment
course for the patient.Reframing judgmental and stigmatizing misconceptions is also important for the
promotion of a culture of harm reduction. Although some HCPs considered the hospital
as protective, patients often experience stigmatization and negative experiences in
the hospital. Prior studies have shown that many PWUD believe they will receive poor
care at the hospital and that HCPs do not care about their lives.[12]
Stigmatization is a key contributor to self-directed discharge, and studies show
that odds of hospital readmission for infections in PWUD who have undergone
self-directed discharge were almost fourfold higher than standard
discharge.[28] The most fundamental aspect of a harm reduction approach is
recognizing that a medical encounter is not an isolated event, but part of a series
of events that shape how a patient thinks about, experiences, and interacts with the
medical system. Addressing stigmatization and mistreatment may reduce traumatizing
hospital experiences for PWUD, allowing them to stay in the hospital long enough to
create a patient-centered treatment and discharge plan through shared
decision-making. Strengthening the patient–provider relationship through the
inclusion of patient preferences in treatment plans, from a harm reduction
perspective, is essential to encouraging future engagement with systems of medical
care and reducing feelings of stigmatization in the hospital. In addition, altering
or eliminating restrictive hospital policies (e.g. smoking, visitors, room searches)
could improve patient experiences while hospitalized and further encourage
engagement with their treatment plan.An important tenet of harm reduction principles is the absence of judgment of PWUD.
Through increased efforts at harm reduction education and offering space for
reflection, HCPs can address their biases and mistrust in PWUD to make ‘good’
decisions. Changing stigmatizing attitudes and behaviors of HCPs, especially those
of experienced providers, can be challenging. Organizations can learn from other
institutions that have adopted approaches to reduce stigma and improve harm
reduction knowledge.[31] It is also important to recognize that there are instances
in which patients lack capacity to make decisions, such as when they are unable to
communicate due to sedation.[32] In reality, it may not be
appropriate to offer every discharge and treatment option to every patient, but if
HCPs approach this decision with a harm reduction approach and without preconceived
judgments about patient capability to make decisions, then there is potentially a
decreased risk of withholding options which may in fact be appropriate for the
patient. However, our study suggests that these decisions should be made with care
and with the entire care team, after considering all possible solutions for existing
barriers to outpatient treatment.Finally, several HCPs were hesitant to offer outpatient treatment because they were
concerned about who held responsibility for adverse patient outcomes if the patient
were to choose a ‘non-standard’ option. Harm reduction-based guidelines and
procedures surrounding treatment and discharge options may address this concern.
Patient-centered decision models informed by an interdisciplinary team of providers,
such as OPTIONS-DC, both support a harm reduction-based approach and disperse
responsibility of the treatment plan among multiple providers.[29]This study adds to existing research on HCP perspectives on the care of PWUD, which
primarily focused on inpatient treatment, access to addiction medicine services, and
attitudes toward PWUD.[33] Englander et al.[34] describe HCP perspectives on
the transition of care from hospital to home and identify many overlapping themes to
this study (such as resource availability and education among care team members) but
do not focus on PWUD or the decision-making process.Our findings should be considered in light of the following limitations. First, we
recruited and interviewed HCPs at a single academic medical center, so our findings
may not be applicable to other hospitals. However, we reached thematic saturation
among lead HCPs in our sample, and our results are consistent with prior literature
on HCP perspectives toward PWUD. Second, examining patient and community
perspectives was out of scope for this article, but future work will include their
perspectives to gain a more comprehensive understanding of this important topic.
Third, our study was conducted during the second year of the COVID-19 pandemic,
which may have altered typical HCP and patient experiences and interactions, beyond
those that might normally be experienced. Fourth, no legal professionals were
interviewed for this study, so debates over liability and legal repercussions were
speculative and therefore a limitation of this study. Finally, due to social
desirability bias, it is possible that some participants may not have voiced their
true opinions during the interviews.
Conclusion
In our study, we found that HCPs perceived several barriers to outpatient care for
patients with IDU-associated infections. Addressing structural drivers of substance
use, utilizing team-based approaches to care, addressing knowledge gaps and
stigmatization, creating an organizational culture of harm reduction, including
patients in treatment conversations, and implementing clear guidelines are all
important for alleviating these barriers and for adopting a harm reduction approach
to discharge decision-making. Even HCPs who adopt a harm reduction approach,
however, may have divergent perspectives on outpatient antimicrobial efficacy and
treatment options. HCPs should thus consider whether remaining hospitalized is more
protective or more harmful than being in the community.
Authors: K M Keyes; M L Hatzenbuehler; K A McLaughlin; B Link; M Olfson; B F Grant; D Hasin Journal: Am J Epidemiol Date: 2010-11-02 Impact factor: 4.897
Authors: Teri Browne; Mary Ann Priester; Stephanie Clone; Aidyn Iachini; Dana DeHart; Robert Hock Journal: J Rural Health Date: 2015-07-15 Impact factor: 4.333
Authors: Ho-Kwong Li; Ines Rombach; Rhea Zambellas; A Sarah Walker; Martin A McNally; Bridget L Atkins; Benjamin A Lipsky; Harriet C Hughes; Deepa Bose; Michelle Kümin; Claire Scarborough; Philippa C Matthews; Andrew J Brent; Jose Lomas; Roger Gundle; Mark Rogers; Adrian Taylor; Brian Angus; Ivor Byren; Anthony R Berendt; Simon Warren; Fiona E Fitzgerald; Damien J F Mack; Susan Hopkins; Jonathan Folb; Helen E Reynolds; Elinor Moore; Jocelyn Marshall; Neil Jenkins; Christopher E Moran; Andrew F Woodhouse; Samantha Stafford; R Andrew Seaton; Claire Vallance; Carolyn J Hemsley; Karen Bisnauthsing; Jonathan A T Sandoe; Ila Aggarwal; Simon C Ellis; Deborah J Bunn; Rebecca K Sutherland; Gavin Barlow; Cushla Cooper; Claudia Geue; Nicola McMeekin; Andrew H Briggs; Parham Sendi; Elham Khatamzas; Tri Wangrangsimakul; T H Nicholas Wong; Lucinda K Barrett; Abtin Alvand; C Fraser Old; Jennifer Bostock; John Paul; Graham Cooke; Guy E Thwaites; Philip Bejon; Matthew Scarborough Journal: N Engl J Med Date: 2019-01-31 Impact factor: 91.245
Authors: Kasper Iversen; Nikolaj Ihlemann; Sabine U Gill; Trine Madsen; Hanne Elming; Kaare T Jensen; Niels E Bruun; Dan E Høfsten; Kurt Fursted; Jens J Christensen; Martin Schultz; Christine F Klein; Emil L Fosbøll; Flemming Rosenvinge; Henrik C Schønheyder; Lars Køber; Christian Torp-Pedersen; Jannik Helweg-Larsen; Niels Tønder; Claus Moser; Henning Bundgaard Journal: N Engl J Med Date: 2018-08-28 Impact factor: 91.245
Authors: Christin N Price; Daniel A Solomon; Jennifer A Johnson; Mary W Montgomery; Bianca Martin; Joji Suzuki Journal: J Infect Dis Date: 2020-09-02 Impact factor: 5.226
Authors: Laura R Marks; Stephen Y Liang; Dharushana Muthulingam; Evan S Schwarz; David B Liss; Satish Munigala; David K Warren; Michael J Durkin Journal: Clin Infect Dis Date: 2020-12-17 Impact factor: 9.079
Authors: Laura C Fanucchi; Sharon L Walsh; Alice C Thornton; Paul A Nuzzo; Michelle R Lofwall Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: E Katherine Nenninger; Jenny L Carwile; Katherine A Ahrens; Brett Armstrong; Kinna Thakarar Journal: Open Forum Infect Dis Date: 2020-02-21 Impact factor: 3.835